Talking Medicines joins 2026 UK AI Index

Tern plc

Talking Medicines has been named in the 2026 UK AI Index, placing it among the top 1,000 AI companies in the country.

The company’s core offering focuses on converting unstructured healthcare dialogue into structured, actionable intelligence for pharmaceutical clients. By applying natural language processing and machine learning to patient and healthcare professional conversations, Talking Medicines helps pharma teams improve how they position medicines, understand brand performance and engage with clinicians. This use of real-world voice data offers a practical solution to the ongoing challenge of making sense of fragmented health communications.

Recognition by the UK AI Index gives Talking Medicines a stronger position within a national network of AI companies that are attracting attention from both investors and policymakers. The index is supported by government and industry groups aiming to map out leadership in artificial intelligence across sectors such as health, finance and energy.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Search